Free Trial

7 Warren Buffett Stocks to Ride Out Market Volatility - 5 of 7

 
 

#5 - Chubb (NYSE:CB)

At a time when Buffett is making headlines for selling his position in certain stocks, it’s notable that he has been buying shares of Chubb Ltd. (NYSE: CB). Buffett is well-versed in insurance companies and the world’s largest publicly traded property and casualty insurance company fits that expertise. With its latest purchases, Berkshire now owns about 6.7% of the company’s stock.  

The latest readings of the consumer price index (CPI) and producer price index (PPI) show the rate of inflation is easing. But that’s deceptive because areas such as home and auto insurance are still showing year-over-year increases. In fact, many homeowners are feeling the pain of higher premiums.  

CB stock has climbed nearly 10% since it reported earnings on July 29, 2024. That's pushed it near its 52-week high. However, analysts have been raising their price targets for the stock that still trades at an attractive 13.7x forward earnings. Plus, Chubb has another attribute that Buffett loves: a safe and growing dividend. In fact, the company has increased its dividend for 31 consecutive years.  

About Chubb

Chubb Limited provides insurance and reinsurance products worldwide. The company's North America Commercial P&C Insurance segment offers commercial property, casualty, workers' compensation, package policies, risk management, financial lines, marine, construction, environmental, medical risk, cyber risk, surety, and casualty; and group accident and health insurance to large, middle market, and small commercial businesses. Read More 
Current Price
$289.84
Consensus Rating
Hold
Ratings Breakdown
9 Buy Ratings, 10 Hold Ratings, 1 Sell Ratings.
Consensus Price Target
$274.70 (5.2% Downside)

 

FDA’s hidden signal greenlights biotech winners — 97% of the time (Ad)

The FDA has started to quietly send out a signal … That has given investors a 97% chance of making money. Perhaps as soon as 9:30 a.m. tomorrow.

Click here to find out how you can get in before the FDA’s potential signal.